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further validated for other chemical classes of developmen-
tal toxicants.
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Introduction
The EU REACH legislation requires the safety assessment 
for new and existing chemicals. At present, regulatory safety 
assessment is predominantly performed using animal models, 
with large numbers of animals needed particularly for devel-
opmental toxicity testing. Therefore, REACH stimulates the 
use of animal-free approaches wherever possible (Hartung 
2009; The European Parliament and the Council 2006). Alter-
native test methods for in vivo developmental toxicity testing, 
accepted for use in regulatory toxicity testing, are urgently 
needed (Höfer et al. 2004). The mouse embryonic stem D3 
(ES-D3) cell differentiation assay is a valuable tool that can 
be used to predict in vivo developmental toxicity potency 
rankings within selected chemical classes for most of the 
chemicals investigated so far (De Jong et al. 2009; Louisse 
et al. 2011; Strikwold et al. 2012). However, as this assay 
does not take kinetic processes into account, it was suggested 
to combine the ES-D3 cell differentiation assay with data on 
kinetics, e.g., placental transfer of compounds, in order to bet-
ter predict in vivo potency of the developmental toxicants (De 
Jong et al. 2009; Louisse et al. 2011; Strikwold et al. 2012). 
We have previously shown that an in vitro BeWo transport 
model is capable of predicting relative placental transfer 
rates of a set of nine model compounds with a good correla-
tion with the relative transport rates observed in the ex vivo 
placental perfusion model (R2 = 0.95), indicating that the 
Abstract The mouse embryonic stem D3 (ES-D3) cell 
differentiation assay is based on the morphometric meas-
urement of cardiomyocyte differentiation and is a promis-
ing tool to detect developmental toxicity of compounds. 
The BeWo transport model, consisting of BeWo b30 cells 
grown on transwell inserts and mimicking the placental 
barrier, is useful to determine relative placental transport 
velocities of compounds. We have previously demonstrated 
the usefulness of the ES-D3 cell differentiation assay in 
combination with the in vitro BeWo transport model to pre-
dict the relative in vivo developmental toxicity potencies 
of a set of reference azole compounds. To further evaluate 
this combined in vitro toxicokinetic and toxicodynamic 
approach, we combined ES-D3 cell differentiation data of 
six novel triazoles with relative transport rates obtained 
from the BeWo model and compared the obtained rank-
ing to the developmental toxicity ranking as derived from 
in vivo data. The data show that the combined in vitro 
approach provided a correct prediction for in vivo devel-
opmental toxicity, whereas the ES-D3 cell differentiation 
assay as stand-alone did not. In conclusion, we have vali-
dated the combined in vitro approach for developmental 
toxicity, which we have previously developed with a set of 
reference azoles, for a set of six novel triazoles. We sug-
gest that this combined model, which takes both toxico-
dynamic and toxicokinetic aspects into account, should be 
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in vitro BeWo transport model is useful to obtain data with 
respect to placental transfer of compounds (Li et al. 2013). 
When combining the BeWo model with the ES-D3 cell dif-
ferentiation assay, for a set of reference azoles, the coeffi-
cient of determination (R2) for correlation of relative in vitro 
potency with relative in vivo potency increased from 0.57 to 
0.95 (Li et al. 2015), showing that the combined approach is 
able to better predict the in vivo developmental toxicity of 
azole antifungal compounds than the stand-alone ES-D3 cell 
differentiation assay.
Our first study included data on five reference antifun-
gal compounds, with four of them being azoles. The azole 
family represents the largest family of antifungal com-
pounds, which can be subdivided into the imidazole and 
triazole groups. We selected the class of azoles, because 
of their widespread use as antifungal agents in medicine 
and crop protection (Menegola et al. 2013) and because 
they are known to cause developmental toxicity, for which 
an extensive toxicity data base is available, required for 
evaluation of predictions made. The reference azoles used 
demonstrated a varying degree of developmental toxic-
ity (Marotta and Tiboni 2010; Stinchcombe et al. 2013), 
allowing for a quantitative assessment of potency, which 
was the basis of the first validation of the combined ES-D3 
and BeWo assay strategy.
The aim of the present study is to further validate the 
combined ES-D3 cell differentiation assay and BeWo 
transport model for predicting in vivo potency of develop-
mental toxicants. To this end, six novel triazoles (Table 1) 
were investigated in the combined in vitro approach and the 
obtained predictions for these compounds were compared 
with the in vivo data that are presented in this paper for the 
first time, not taken from the literature.
Materials and methods
Chemicals
BASF triazoles 0594 ([5-(4-chloro-2-fluoro-phenyl)-3-(2,4- 
difluoro-phenyl)-isoxazol-4-yl]-pyridin-3-yl-methanol), 
0595 ([2,4-bis-(2,4-difluoro-phenyl)-thiophen-3-yl]-pyridin- 
3-yl-methanol), 0596 (4-{2-[2-(4-fluoro-phenyl)-2-hydroxy- 
1-methyl-3-[1,2,4]triazol-1-yl-propyl]-thiazol-4-yl} 




4-triazole) and 0618 (4-methyl-1,3-dioxolan-2-yl-
methyl-1,2,4-triazole derivate) were kindly provided by BASF 
SE (Ludwigshafen, Germany). Dimethyl sulfoxide (DMSO) 
was purchased from Acros Organics (Geel, Belgium).
BeWo transport experiments
To study placental transfer of test compounds, BeWo 
transport experiments were performed as described previ-
ously (Li et al. 2013). Briefly, BeWo b30 cells (passages 
27–45) were cultured in DMEM (Zwijndrecht, The Neth-
erlands), supplemented with 10 % (v/v) heat-inactivated 
FCS (HyClone-Perbio, Etten-Leur, The Netherlands), 
10,000 U/ml penicillin, 10 mg/ml streptomycin and 
2 mM l-glutamine. The cells were seeded at a density of 
1 × 105 cells/cm2 on transwell® polycarbonate membranes 
(12 mm diameter, 0.4 μm pore size) (VWR International 
BV, Amsterdam, The Netherlands) coated with human pla-
cental collagen. The medium (0.5-ml apical compartment, 
1.5-ml basolateral compartment) was replaced daily. At 
day 6 postseeding, the BeWo b30 cell layers were used for 
transport experiments. The barrier-forming capacity of the 
BeWo cell layers was evaluated by measuring the transepi-
thelial electrical resistance (TEER) of the cell monolayer 
using a Millicell ERS-2 Volt-Ohm Meter (Millipore, USA) 
at day 6 postseeding as described previously (Li et al. 
2013). Only the cell layers showing TEER values between 
80 and 100 Ω cm2 were used for transport experiments.
Transport experiments were initiated by adding 0.5 ml 
of transport buffer Hank’s balanced salt solution (HBSS, 
Invitrogen, Breda, The Netherlands) containing the test 
compound, being 0594, 0595, 0596, 0599, 0600 and 0618, 
dissolved in DMSO (final solvent concentration 0.5 % 
DMSO), at concentration of 50 μM, to the apical compart-
ment and 1.5 ml transport buffer to the basolateral compart-
ment. Subsequently, the plate was incubated in a humidified 
Table 1  Chemical information of six triazoles tested in the present study






0618 4-Methyl-1,3-dioxolan-2-yl-methyl-1,2,4-triazole derivate 440.0
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atmosphere with 5 % CO2 at 37 °C. After 15, 30, 60 and 
90 min, a sample of 0.2 ml was taken from the basolateral 
compartment and replaced by an equal volume of transport 
buffer. At the end of each experiment, a 0.2-ml sample was 
also taken from the apical compartment. Subsequently, the 
filters with the BeWo b30 cell layers were washed three 
times with PBS, cut out of the insert, dissolved in 0.25 ml 
65 % (v/v) methanol and sonificated for 15 min in a Ban-
delin Sonorex RK100 (Berlin, Germany) in order to deter-
mine the amount of compound accumulated in the cells. 
After each experiment, mass balance calculations were per-
formed. In each transport study, amoxicillin and antipyrine 
were included as control and reference compounds. Amoxi-
cillin transport was included to assess for monolayer integ-
rity since it is a compound known to be transported only to 
a limited extent across the placenta, whereas antipyrine was 
included as a control for optimal transport and a reference 
compound to enable calculation of relative transport rates 
(Li et al. 2013). The transport of the six test compounds, 
as well as the reference compounds amoxicillin and anti-
pyrine, through the permeable membrane of the transwell 
filter in the absence of BeWo cells was determined as well. 
The transport to the basolateral compartment was shown to 
be equally fast for all compounds (data not shown), ensur-
ing that any differences observed in the transport studies 
were related to the BeWo cell layer and not to the filter. For 
each test compound, three independent experiments were 
performed, with three technical replicates per experiment.
High‑performance liquid chromatography analysis
Samples were analyzed using high-performance liquid 
chromatography (HPLC) to quantify the amount of test 
compound in order to determine the transport rate and to 
perform mass balance calculations. The HPLC system used 
consisted of a Waters (Milford, MA) 600 controller and a 
600 pump, equipped with a photodiode array detector set to 
record absorption of wavelengths between 200 and 400 nm. 
A Waters 717 plus autosampler was used for sample injec-
tion. The temperature of the autosampler was kept at 7 °C.
For analysis of all compounds, 50 μl sample was injected 
to a C18 5 μm reverse-phase column (150 mm × 4.6 mm 
I.D.) with a guard column (7.5 mm × 4.6 mm I.D.) 
(Alltech, Bergen op Zoom, The Netherlands). The mobile 
phase used for analysis of all the test compounds consisted 
of (A) 0.1 % trifluoroacetic acid in nanopure water and 
(B) HPLC-grade acetonitrile. Elution was at a flow rate 
of 0.8 ml/min, starting at 22 % B with a linear increase to 
100 % B in 8 min. Subsequently, the gradient returned lin-
early to the initial condition in 10 min and remained 2 min 
at this condition prior to the next injection. In each analy-
sis, calibration curves of all compounds were included for 
quantification.
ES‑D3 cell culture
The murine ES-D3 cell line was purchased from ATCC 
(Wesel, Germany). The cells were maintained in polysty-
rene cell culture flasks (Corning, The Netherlands) in Dul-
becco’s modified Eagle’s medium (DMEM, Invitrogen, 
Breda, The Netherlands), supplemented with 20 % heat-
inactivated fetal calf serum (Lonza, BioWhittaker, Verviers, 
Belgium), 50 U/ml penicillin with 50 μg/ml streptomy-
cin (Invitrogen), 2 mM l-glutamine (Invitrogen), 0.1 mM 
β-mercaptoethanol (Sigma-Aldrich) and 1 % (v/v) nones-
sential amino acids (Invitrogen), at 37 °C and 5 % CO2 in 
a humidified atmosphere. Cells were kept undifferentiated 
with 1000 U/ml murine leukemia inhibiting factor (LIF) 
(Sigma-Aldrich) and subcultured every 2–3 days using 
nonenzymatic cell dissociation solution (Sigma-Aldrich) to 
detach the cells.
Cytotoxicity assay with ES‑D3 cells
To determine cytotoxicity of the compounds, a WST-1 
assay was performed. This assay measures the influence 
of test compounds on the formation of the water-soluble 
formazan reaction product from WST-1 by mitochon-
drial succinate-tetrazolium reductase enzymes. The cyto-
toxicity of a test compound inversely correlates with the 
absorbance of the produced formazan quantified spectro-
photometrically as described previously (Reitsma et al. 
2013). ES-D3 cells were exposed to test compounds 
for the duration of 1 or 5 days as described before (Li 
et al. 2015). Briefly, cells were seeded in 96-well plates 
(Greiner bio-one) at concentrations of 20 × 104 cells/ml 
(1-day exposure) or 1 × 104 cells/ml (5-day exposure) in 
100 μl culture medium in the absence of LIF and incu-
bated for 1 day to allow cell adherence. Then, the cells 
were exposed to the test compounds at concentrations 
up to 60 μM (final solvent concentration 0.2 % DMSO) 
and subsequently cultured for 1 or 5 days at 37 °C and 
5 % CO2 in a humidified atmosphere. Solvent DMSO 
(0.2 %) was used as a negative control and 1 % Tri-
ton X-100 served as a positive control in all cytotoxic-
ity assays. After incubation of 1 or 5 days, 20 μl WST-1 
reagent (Roche, Woerden, The Netherlands) was added 
to each well and the plates were incubated for another 
3 h. Then, absorbance was measured at 450 nm using a 
SpectraMax M2 (Molecular Devices, Sunnyvale, USA). 
Three wells were used per treatment in each independent 
experiment. Three independent experiments were done 
for each compound. The cell viability was expressed as 
% of the solvent control, with the solvent control set at 
100 % viability. Reproducible results were obtained from 
the treatments of negative and positive controls in all of 
the cytotoxicity assays.
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Differentiation assay with ES‑D3 cells
Differentiation assays were carried out to detect the effect 
of test compounds on the differentiation of ES-D3 cells 
into contracting cardiomyocytes using culture medium in 
the absence of LIF. On day 1, droplets of 20 μl cell suspen-
sion (3.75 × 104 cells/ml) were placed as hanging drops, to 
which the test compounds 0594, 0595, 0596, 0599, 0600 
and 0618 were added at concentrations ranging from 0.2 
to 60 μM (final solvent concentration 0.2 % DMSO), on 
the inner side of the lid of a 96-well plate. Sterile lids of 
Eppendorf tubes were placed on the corner wells of the 
plates to prevent contact of the drops with the plate. The 
wells of the 96-well plate were filled with 250 μl phos-
phate buffered saline (PBS) (Invitrogen), and the plate 
was sealed with Micropore tape (3M, Neuss, Germany) 
to prevent evaporation of the hanging drops. Plates were 
incubated for 3 days at 37 °C and 5 % CO2 in a humidified 
atmosphere. In the drops, cells formed embryonic bodies 
(EBs), which were transferred to nontissue culture-treated 
Petri dishes (diameter 6 cm, Greiner) with 5 ml of medium 
with test compound. On day 5, the EBs were transferred to 
a 24-well plate (Corning) with 1 ml of medium with test 
compound, with one EB per well. On day 10, the number 
of wells containing contracting EBs was determined by 
visual inspection using a light microscope. Solvent control 
(0.2 % DMSO in culture medium) was included in each 
experiment. The solvent control was also used to assess the 
quality of the batch of ES-D3 cells used in each individual 
test (cells being randomly distributed over test groups and 
solvent control). Tests were accepted for further analysis if 
at least 21 of the 24 wells of the solvent control contained 
contracting cardiomyocytes. For each test compound, 
three independent assays were performed. The results 
were expressed as “fraction of total,” with 1.0 implying 
all EBs in one 24-well plate differentiated into contracting 
cardiomyocytes.
In vivo experiments
The in vivo investigations of maternal and prenatal devel-
opmental toxicity were performed as a screening approach 
following the general principles of OECD 414 and OPPTS 
870.3700 test guidelines, and the OECD and US Environ-
mental Protection Agency Good Laboratory Practice Stand-
ards [40 CFR Part 160 (FIFRA) and Part 792 (TSCA)]. The 
major differences to a full guideline study were the smaller 
sample size, using 9–10 instead of at least 16 pregnant rats, 
per test substance. Furthermore, the fetal evaluation was 
performed using 4–10 l, the lower number being used if 
sufficient (i.e., positive) results were obtained to assess the 
prenatal developmental toxicological potential of the test 
compounds. The in vivo studies were performed according 
to the German Animal Welfare Act, the European Council 
Directive 2010/63/EU and in an AAALAC-accredited facil-
ity. This screening study of developmental compounds was 
approved by the local authorizing agency for animal exper-
iments (Landesuntersuchungsamt Koblenz, Germany) as 
referenced by the approval number 23 177-07/G08-3-008).
Test animals
The animals were paired by the breeder [time-mated Wistar 
rats, Crl: WI (Han), Charles River Laboratories, Sulzfeld, 
Germany], between 10 and 12 weeks of age, and supplied 
on the day of evidence of mating; this day is referred to 
as gestational day (GD) 0 and following day as GD 1. All 
animals showed no clinical signs of disease. This strain 
has been extensively used, both in our laboratory and else-
where, and is sensitive to reproductive toxicants. All rats 
were housed individually in Makrolon cages with Ligno-
cel PS 14 fibers dust-free bedding and wooden enrichment 
blocks. The cages were kept in climate-controlled rooms 
at 20–24 °C with a relative humidity of 30–70 %, an air 
exchange rate of 15 times per hour and a 12-h light/dark 
cycle. Diet (Ground Kliba SA, Switzerland) and tap water 
were provided ad libitum. In-life data (mortality, clinical 
signs, body weights and food consumption) were recorded 
throughout the study, but presented only if relevant for the 
interpretation of prenatal developmental effects.
Experimental procedure
Studies were conducted with daily oral administration of 
test substances by gavage (test compounds 0594, 0595, 
0596, 0599 and 0600) or via diet (test compound 0618) 
from GD 6 to GD 19 (Table 4). The individual dose levels 
were selected based on the results of a repeated exposure 
to nonpregnant female rats over 14 days (data not shown). 
According to the OECD 414 test guideline, it was aimed 
to cause signs of maternal toxicity as recommended at the 
high-dose level. The test compounds administered by gav-
age were administrated between 100 and 600 mg/kg bw/
day using the vehicle 1 % carboxymethylcellulose in deion-
ized water. The standard dose volume was 10 ml/kg bw. 
The test compound 0618 was administered via the diet at 
dose levels of 300 ppm (dose was reduced from 2500 ppm 
on GD 6 and 7 causing severe clinical signs) and 1000 ppm 
in the diet. The exposures were corresponding to a sub-
stance intake of 28 mg/kg bw/day (GD 8–19) and 69 mg/
kg bw/day (GD 6–19), respectively.
Necropsy and fetus preparation
On GD 20, the surviving dams were anesthetized with isoflu-
rane, killed by decapitation and examined macroscopically. 
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For each dam, the uterus was opened and the number, dis-
tribution and classification of implantation sites (live fetus, 
early and late fetal resorptions, and dead fetus) were deter-
mined. The fetuses were removed, sexed and fetal body 
weight determined. Gross pathological examination of the 
fetuses, including assessment of abnormalities of the fetal 
membranes, placentas, amniotic fluid and umbilical cord, 
was performed. Subsequently, all fetuses were killed by 
injection of pentobarbital. About half of the fetuses of each 
dam were fixed in ethyl alcohol and after fixation, stained 
according to a modified method of Dawson (1926) to show 
the skeleton. The other half of the fetuses of each dam was 
fixed in Harrison’s fluid. After fixation, the soft tissue of 
these fetuses was examined according to a modified micro-
dissection method (Barrow and Taylor 1969). The glossary 
of Wise et al. (1997) and its updated version of Makris et al. 
(2009) were essentially used to describe findings in fetal 
morphology. Classification of these findings was based on 
the terms and definitions proposed by Chahoud et al. (1999) 
and Solecki et al. (2001, 2003). A permanent structural 
change that is likely to affect adversely the survival or health 
was assessed as malformation. A change that also occurs 
in the fetuses of control animals and/or is unlikely to affect 
adversely the survival or health was assessed as variation. 
This includes delays in growth or morphogenesis that have 
otherwise followed a normal pattern of development.
Data analysis
BeWo transport data
For each compound, the linear appearance rate in the baso-
lateral compartment was determined. These linear appear-
ance rates were used to calculate apparent permeability 
(Papp) coefficients [Papp coefficient (cm/s) = (ΔQ/Δt)/
(A × C0)], where ΔQ is the amount of test compound 
(nmol) transported to the receiver chamber in a certain 
time span [Δt (s)], A is the cell surface area (cm2) and C0 
is the initial concentration of the test compound (µM). To 
calculate ΔQ, a correction was made to compensate for 
the removal of compound when taking samples [ΔQ at 
tx+1 = amount measured at tx+1 (nmol) (basolateral con-
centration at tx+1 (μM) × 1.5 (ml)] supplemented with the 
amount removed at tx (nmol) [basolateral concentration 
sample at tx (μM) × 0.2 (ml)]. Subsequently, relative Papp 
values were determined by expressing the Papp coefficient 
as a fraction of the Papp coefficient obtained for antipyrine.
In vitro ES‑D3 differentiation data
Different dichotomous concentration–response mod-
els were fitted to the in vitro developmental toxicity data 
obtained from the ES-D3 cell differentiation assay to 
calculate benchmark concentrations (BMC) using Environ-
mental Protection Agency benchmark dose (BMD) soft-
ware version 2.4. For each test compound, the BMCd50, 
representing the concentration for a 50 % reduction in 
the number of differentiated EBs, was derived. Models 
included in the evaluation were the gamma, logistic, loglo-
gistic, probit, logprobit, multistage, weibull and the quan-
tal-linear model. Goodness of fit of the models was evalu-
ated to accept a model, based on the p values, the scaled 
residuals and the graphical displays obtained. The lowest 
BMCd50 value was chosen from the accepted models.
Figures of concentration–response curves for both dif-
ferentiation and cytotoxicity were made using Graph-
Pad Prism 5 using a four-parameter logistic model. These 
curves were not used for the derivation of the BMDd50 val-
ues since BMDd50 values were derived as described above 
using BMD modeling.
To combine in vitro developmental toxicity data 
obtained from the ES-D3 cell differentiation assay with 
placental transfer data obtained from the BeWo transport 
model, a corrected BMCd50 value was calculated by divid-
ing the BMCd50 values by the relative Papp values, as 
described in Li et al. (2015).
In vivo data
Data obtained for food consumption, body weight, carcass 
weight, weight of unopened uterus, weight of placentas and 
fetuses, the number of implantations, number of late fetal 
resorptions and percentage of postimplantation loss were 
analyzed by a simultaneous comparison of all dose groups 
with the control group using Dunnett’s test (Dudewicz et al. 
1975; Dunnett 1964). The number of pregnant animals at 
the end of the study, mortality rate of the dams and number 
of litters with fetal findings were analyzed by Fisher’s exact 
test (Siegel 1956) and the proportion of fetuses with findings 
per litter by Wilcoxon signed-rank test (Hettmansperger and 
McKean 1978; Siegel 1956). Maternal toxicity was classi-
fied as slight if body weight and/or carcass weight reduction 
is not above 10 %, moderate if body weight and/or carcass 
weight reduction is between 10 and 20 % and severe if body 
weight and/or carcass weight reduction is above 20 %. All 
the in vivo data are expressed as the affected fetuses/litter.
Results
In vitro BeWo transport
For all transport experiments, the mass balances were 
between 91 and 99 %. Figure 1 shows the increasing amount 
of test compounds in the basolateral compartment of the 
BeWo model over time, after adding 25 nmol to the apical 
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compartment. Antipyrine was included as a reference com-
pound known to be efficiently transported across the BeWo 
cell layer, and amoxicillin was used as a control compound to 
check the integrity of the cell layer (Li et al. 2013). The slow 
transfer of amoxicillin indicated an intact BeWo cell layer. 
For up to 60 min, the transport of all compounds to the baso-
lateral compartment was linear in time. Therefore, the linear 
appearance rate of compound in the basolateral compartment 
could be determined using data at 30 min for the calculation 
of Papp coefficients. The data in Table 2 show a wide (up to 
eightfold difference) range of Papp coefficients for the six 
test compounds, illustrating different placental transfer rates 
among them, with 0596 being transported at the highest rate 
and 0595 at the lowest rate. Besides the transport rate, intra-
cellular accumulation of six test compounds and the control 
compounds at 90 min was quantified and the results obtained 
are shown in Table 2. The data show that all triazoles tended 
to accumulate in the BeWo cells and that amoxicillin and 
antipyrine did not. Higher amounts of 0595, 0600 and 0618 
were detected in the cells than of the other three triazoles.
Cytotoxicity assay with ES‑D3 cells
WST-1 assays for both 1- and 5-day exposure were per-
formed to evaluate the cytotoxic effects of the compounds on 
the ES-D3 cells (Fig. 2). For all compounds, the concentra-
tions tested (up to 60 μM) were noncytotoxic as determined 
in the 1-day cytotoxicity assay. Among the six compounds, 
0618 was the most potent one in the 5-day cytotoxicity assay, 
reducing the cell viability to 10 % at 60 μM. Exposure of 
60 μM 0599, 0596 and 0594 to the ES-D3 cells resulted in 
80, 70 and 30 % decline in cell viability, respectively, reflect-
ing lower cytotoxic properties. The least cytotoxic triazoles 
were 0595 and 0600, which caused slight reduction in cell 
viability (20 %) up to 60 μM.
Differentiation assay with ES‑D3 cells
To study the in vitro developmental toxicity of the antifun-
gal triazoles, the effect of the compounds on the differen-
tiation of ES-D3 cells into contracting cardiomyocytes was 
evaluated. All test compounds induced a concentration-
dependent inhibition of the differentiation of the ES-D3 
cells into contracting cardiomyocytes (Fig. 2). The cal-
culated BMCd50 values were at concentrations that did 
not cause cytotoxicity (after 1 and 5 days), indicating that 
inhibitory effects on the differentiation of EBs are not due 
to cytotoxicity of the test compounds. BMCd50 values are 
summarized in Table 3, showing that 0599 was the most 
potent in inhibiting the differentiation of EBs, followed by 
0600 > 0618 > 0594 > 0595 > 0596.
Combination of in vitro developmental toxicity data 
with BeWo transport data
To combine in vitro developmental toxicity data obtained 























Fig. 1  Amount of 0594 (open circle), 0595 (filled circle), 0596 (filled 
triangle), 0599 (times symbol), 0600 (filled square), 0618 (hyphen 
symbol), amoxicillin (open triangle) and antipyrine (open diamond 
symbol) in the basolateral compartment in the in vitro BeWo model 
with increasing time using initial concentrations of 50 μM (25 nmol) 
in the apical compartment. Data are presented as mean ± SD (n = 3)
Table 2  Papp coefficients 
at 30 min and relative Papp 
values of six test compounds 
and the reference compounds 
amoxicillin and antipyrine in 
the BeWo model
a Mean ± SD
Compounds Intracellular accumulation  
(% of added amount)




Amoxicillin 0 6.5 ± 0.2a 0.16
0594 24 11.5 ± 2.6 0.30
0595 79 3.0 ± 0.4 0.08
0596 12 24.4 ± 2.7 0.63
0599 22 18.4 ± 1.1 0.47
0600 66 7.9 ± 1.0 0.20
0618 56 7.1 ± 0.2 0.18
Antipyrine 0 38.9 ± 3.0 1.00
1231Arch Toxicol (2016) 90:1225–1237 
1 3
transfer data obtained from the BeWo transport model, a 
corrected BMCd50 value was calculated by dividing the 
BMCd50 values by the relative Papp values (Table 3). After 
the correction, the potency ranking was altered, being 059
9 > 0596 > 0600 > 0594 > 0618 > 0595.
Potency ranking derivation from in vivo data
In the in vivo studies, all tested compounds showed, to 
some degree, a potential to cause prenatal developmental 
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Fig. 2  Concentration-dependent effects of test compounds 0594 (a), 
0595 (b), 0596 (c), 0599 (d), 0600 (e) and 0618 (f) on cell viabil-
ity for 1-day (times symbol) and 5-day (open circle) exposure and on 
inhibition of ES-D3 cell differentiation (open triangle). Figures pre-
sent data of three independent experiments
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relevant alterations relative to controls are summarized 
in Table 4. The potency of each of the test compounds to 
cause prenatal developmental toxicity was assessed based 
on the observed fetal findings, including teratogenic effects, 
taking into account the presence or absence of maternal 
toxicity at the different dose levels.
The highest potential to cause prenatal developmen-
tal toxicity, based on the results of the in vivo studies, 
was observed for the test compound 0599 (ranking 1). It 
caused teratogenic effects in 100 % of fetuses, manifested 
in skeletal malformations on the tuberositas deltoidea and 
pterygoid bones as well as palate at 100 mg/kg bw/day. 
This dose level did not alter the overall development of the 
fetuses indicated by their body weight or in utero survival 
indicated by resorption rate. At this exposure, maternal tox-
icity was observed noted as decreased food consumption 
(74 % GD 6–20), body weight change (66 % GD 6–8) and 
carcass weight (91 %). Maternal toxicity is not considered 
to have contributed significantly to the fetal effects.
The second highest potential to cause prenatal develop-
mental toxicity was observed for the test compound 0596 
(ranking 2). This compound also caused teratogenic effects 
in all fetuses, manifested in skeletal malformations, like 
the test compound 0599. The malformation observed at the 
highest incidences was observed in skull bones (includ-
ing basisphenoid) and cervical arches. But this time all 
fetuses were only affected at a six-time higher dose level of 
600 mg/kg bw/day. Comparable to the test substance 0599, 
this dose level did not affect the overall development of the 
fetuses indicated by their weight or in utero survival indi-
cated by resorption rate being comparable to the control. 
The teratogenic effects were observed at a dose level caus-
ing almost no maternal toxicity, only visible in an increased 
placental weight (133 %). At 200 mg/kg bw/day, the pat-
tern of treatment-related effects was comparable to 600 mg/
kg bw/day, but malformations being observed in 47 % of 
fetuses per litter.
The third highest potential to cause prenatal develop-
mental toxicity was observed for the test compound 0600 
(ranking 3). It was causing treatment-related findings 
neither on fetuses nor on dams at 200 mg/kg bw/day. At 
600 mg/kg bw/day, the teratogenic potential of the test 
compound was manifested in an increased incidence of 
skeletal malformations (81 % of fetuses per litter) with-
out affecting the fetal growth or causing increased number 
of resorptions. The significantly increased malformation 
rate was observed in small or absent tuberositas deltoidea, 
misshapen pterygoid bones and cleft palate. The mater-
nal toxicity observed in lower body weight changes in the 
beginning of exposure (27 % GD 6–8), and the increased 
placental weight (130 %) might had enhanced the severity 
of teratogenic effects but could not be encountered for their 
occurrence only.
The third lowest potential to cause prenatal develop-
mental toxicity was observed for the test compound 0594 
(ranking 4). Like the test compound 0600, it did not cause 
treatment-related findings in fetuses and dams at 200 mg/
kg bw/day. At 600 mg/kg bw/day, only slight maternal tox-
icity was observed in minor alterations of food consump-
tions (86 % GD 6–8) without any effect on the body weight 
development of the dams. A borderline increase in post-
implantation loss was determined with 14.9 % being only 
slightly above the spontaneous incidence of 14.7 % given in 
the historical control data for this rat strain in our test facil-
ity. In comparison with test compound 0600, a weaker tera-
togenic potential of the test compound 0594 was observed 
manifested in an increased total skeletal malformation inci-
dence of 12.5 % fetuses per litter (bent femurs) at 600 mg/
kg bw/day. This dose did not significantly affect number of 
fetuses alive per litter or the growth of the fetuses.
The second lowest potential to cause prenatal develop-
mental toxicity was observed for the test compound 0618 
(ranking 5). It caused slight or moderate maternal toxicity 
at 300 and 1000 ppm manifested in significantly decreased 
body (87 % at 1000 ppm) and/or decreased carcass weight 
(95 % at 300 ppm and 83 % at 1000 ppm). The highest 
dose level tested also caused significantly increased pla-
cental weights (162 %) and postimplantation loss (30.3 %). 
The latter was based mainly on the increased number of 
late resorptions (23.2 %). The observed decreased fetal 
development manifested in the lower fetal body weight 
(87 % at 1000 ppm) could partially be explained by the 
moderate maternal toxicity observed. However, the skeletal 
malformation observed here, low incidences of bent femur, 
is a rare finding and is not in the historical control data. 
Thereby, the test compound 0618 still demonstrated a weak 
teratogenic potential.
The lowest potential to cause prenatal developmental 
toxicity was observed for the test compound 0595 (ranking 
6). It has a relatively high general toxic potential leading 
Table 3  BMCd50 values for in vitro developmental toxicity of test 
compounds in the ES-D3 cell differentiation assay and corrected 
BMCd50 values obtained by combining the ES-D3 cell differentiation 
assay data with data on placental transfer from the BeWo transport 
model
a Corrected BMCd50 value was calculated by dividing the BMCd50 
values by the relative Papp values
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to poor general state in 3 out of 10 rats after 10–11 days 
of exposure to 600 mg/kg bw/day. These animals had been 
killed moribund on GD 15 and 16. The surviving dams 
showed severe maternal toxicity in decreased body (74 %) 
and carcass (89 %) weight. At this dose level, none of the 
embryos survived the in utero exposure leading to 100 % 
early resorptions. At 200 mg/kg bw/day, no maternal toxic-
ity but still a significant increase in postimplantation loss 
(24 %) was observed mainly caused by an increase in num-
ber of early resorptions (21.9 %). The surviving fetuses did 
not show alterations on growth or malformations. Thereby, 
no teratogenic potential was observed for the test substance 
0595 in this in vivo study.
Based on this assessment, a developmental potency 
ranking of the test compounds was obtained: 0599 > 0596 
> 0600 > 0594 > 0618 > 0595.
Comparison of in vivo and in vitro developmental 
toxicity ranking
Both in vitro developmental toxicity potency rankings 
based on BMCd50 alone and the placental transfer cor-
rected BMCd50 values were compared with in vivo potency 
ranking, to assess the usefulness of combining data from 
the ES-D3 cell differentiation assay with data from the 
BeWo transport model to predict in vivo potency rank-
ing (Table 5). Based on the in vivo ranking, 0599 was the 
most potent compound in vivo and 0595 was the least 
potent one. The potency ranking of the six test compounds 
in the ES-D3 cell differentiation assay correlates to some 
extent with the in vivo ranking, with 0599 being the most 
potent one, however, with clear differences for the less 
toxic ones. For 0596, especially, the relative potency is 
not well predicted in the ES-D3 assay, being least toxic in 
the ES-D3 cell differentiation assay, whereas almost most 
toxic in vivo. When the ES-D3 cell differentiation data are 
combined with the results obtained in the BeWo transport 
model to obtain corrected BMCd50 values, a better correla-
tion with the in vivo ranking was obtained with no discrep-
ancy (Table 5). These data thus demonstrate the power of 
including a component of kinetics when predicting relative 
in vivo toxicity potencies based on in vitro toxicity data.
Discussion
The ES-D3 cell differentiation assay has shown to be a prom-
ising method to assess the developmental toxicity potency 
ranking of series of structurally related compounds in vitro, 
and it has been suggested that the capacity of this assay to 
predict in vivo potency ranking could be improved by com-
bining kinetic information with the in vitro data (De Jong 
et al. 2009; Louisse et al. 2011; Strikwold et al. 2012). We 
have previously demonstrated that the ES-D3 cell differentia-
tion assay combined with the in vitro BeWo transport model 
for placental transfer is able to better predict the in vivo 
developmental toxicity of a set of reference azoles, than as a 
stand-alone assay (Li et al. 2015). In this study, we extended 
the dataset, to validate this combined model by testing more 
compounds within the series of antifungal triazoles.
The in vitro BeWo transport model was used to obtain 
the relative transport rate in the present study, as it was 
previously shown to be suitable to adequately character-
ize relative placental transfer rates of compounds (Carreira 
et al. 2011; Li et al. 2013; Poulsen et al. 2009). The six test 
compounds showed different transfer rates (up to eightfold) 
through the placental barrier in the BeWo model, indicat-
ing that transport velocities to the fetus in vivo may differ 
as well. However, how this exactly translates to differences 
in fetal exposure is not known, due to the fact that in vivo 
experimentation of placental transport in humans is not fea-
sible on a large scale for obvious ethical reasons and also 
because little has been published on the fetal bioavailabil-
ity of antifungal compounds in vivo. We hypothesize that 
the extent of fetal exposure would be positively correlated 
with the relative transport velocity in the BeWo model. 
Therefore, we investigated whether the correlation between 
in vitro BMCd50 value-based potency ranking and in vivo 
developmental toxicity potency ranking would improve 
when we corrected the in vitro BMCd50 values for differ-
ences in placental transfer, by dividing these BMCd50 val-
ues for the six test compounds in the ES-D3 cell differen-
tiation assay by relative Papp values obtained in the BeWo 
model.
With the ES-D3 cell differentiation assay alone, the pre-
dicted toxic concentrations among the six test compounds 
Table 5  Comparison of the in vivo developmental toxicity ranking of test compounds with the ES-D3 cell differentiation alone or with the 
ES-D3 cell differentiation assay combined with the BeWo transport model
Methods Toxicity ranking
Least toxic → Most toxic
ES-D3 0596 0595 0594 0618 0600 0599
ES-D3 + BeWo 0595 0618 0594 0600 0596 0599
In vivo 0595 0618 0594 0600 0596 0599
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were within the same order of magnitude, but the combined 
assays resulted in a different ranking, with the most potent 
compound being about 30 times more toxic than the least 
potent one. The results obtained reveal that the ranking 
according to the corrected BMCd50 values correlated bet-
ter than the uncorrected ones with the ranking that could 
be derived from in vivo developmental toxicity data. This 
shows that combining the ES-D3 cell differentiation assay 
results with placental transfer kinetic data improved the 
ability of this in vitro assay to predict in vivo developmen-
tal toxicity potencies of the tested compounds. It should be 
noted that other important in vivo kinetic processes than 
placental transfer, such as intestinal absorption, mater-
nal metabolism and placental metabolism, were not taken 
into account and that these will contribute to the amount 
of compound available in the fetus. Therefore, incorporat-
ing more kinetic information is likely to further improve 
the predictive value of the ES-D3 cell differentiation assay. 
Besides, the BeWo cell model may not be suitable to deter-
mine the absolute transport rates of compounds, given that 
the BeWo cell model is a simplification of the in vivo pla-
cental transfer system. In those cases where it is important 
to use exact fetal bioavailability values, physiologically 
based kinetic (PBK) models, which describe the in vivo 
absorption, distribution, metabolism and excretion pro-
cesses of a compound should be used for the translation of 
in vitro toxicity data to the in vivo situation (Louisse et al. 
2010, 2014; Strikwold et al. 2013).
We acknowledge that the increase in placental weight, 
noted for 0596 (at 200 and 600 mg/kg bw/day), 0599 (at 
600 mg/kg bw/day) and 0618 (at 1000 ppm) in the rat stud-
ies cannot be reflected in the ES-D3 assay, and therefore, 
these effects were not taken into account when making the 
comparison among the different triazoles. The increased 
placental weight in pregnant rat may be the result of inhi-
bition of aromatase enzyme activities (Stinchcombe et al. 
2013). The contribution of placental changes induced by 
azole compounds to fetal development and its relevance to 
humans is currently under investigation (Rey Moreno et al. 
2013).
In this study, intracellular accumulation of test com-
pounds in the placental cells was investigated in the 
BeWo cell model. Triazoles 0595, 0600 and 0618 showed 
a high percentage of accumulation, up to 79 % of the 
total mass added, in the BeWo cells. If this accumulation 
in placental cells is also occurring in vivo, the accumu-
lated compounds may potentially affect the development 
or function of the placenta, given that the placenta is an 
entry organ to the fetus and vulnerable to the adverse 
effects of many toxicants. Structural or functional damage 
to the placenta can lead to adverse effects, such as abor-
tion, birth defects and stillbirth. We observed that tria-
zole 0595, which showed the highest accumulation in the 
BeWo cells, induced the highest level of postimplantation 
loss, making it tempting to speculate that there might be 
a link between the BeWo cellular accumulation and the 
in vivo resorption rate. However, as BeWo cells only rep-
resent part of the placental tissue and since placental tis-
sue changes over pregnancy, it is difficult to translate this 
in vitro finding to the exact in vivo situation. Results on 
placental accumulation of the six triazoles in vivo are not 
available, but it has been elucidated that some pesticides 
were found to accumulate in placental tissue (Mohan and 
Singh 2013; Saxena et al. 1981). Therefore, it might be of 
interest to pay attention to possible placental toxicity, for 
which the in vitro BeWo cell model might be useful for 
prioritization because as shown in the present study the 
model is able to provide information on the intracellular 
accumulation of compounds.
The ES-D3 cell differentiation assay is considered to 
represent the fetal component of developmental toxicity. 
However, the (azole) antifungal compounds are found to 
have the ability to inhibit cytochrome enzymes (Marotta 
and Tiboni 2010) and in particular may inhibit estrogen 
biosynthesis through CYP19 aromatase inhibition, reduc-
ing the conversion of androgens to estrogens and exert-
ing endocrine disrupting effects (Kjærstad et al. 2010b). 
This process takes place in the maternal organism, and the 
phenotypic analysis of the inhibition of cardiac differen-
tiation in the ES-D3 cell differentiation assay cannot take 
this part of developmental toxicity into account. Therefore, 
other relevant in vitro assays, such as the steroidogenesis 
assay (Kjærstad et al. 2010b; Stresser et al. 2000), may be 
needed. In addition, although we have proven in the pre-
vious and the present study that the ES-D3 cell differen-
tiation assay combined with the BeWo transport assay 
shows to be an appropriate in vitro toxicological system 
to achieve an enhanced predictivity of the relative devel-
opmental toxicity for antifungal compounds, one should 
still note that one single alternative testing approach is not 
likely able to predict for the entire scope of developmental 
toxicants. To obtain information on mechanisms underly-
ing developmental toxicity, the ES-D3 cell differentiation 
assay could be combined with transcriptomics analyses, 
which can be used to group compounds in classes based on 
toxicity mechanisms (van Dartel and Piersma 2011). A tool 
box which integrates different relevant in vitro assays into 
an integrated testing strategy may provide the best possible 
strategy to characterize both the toxicological profile and 
the relevant mechanistic information for human chemical 
risk assessment.
When it comes to risk assessment, it should be remem-
bered that many antifungal products contain mixtures of 
active substances, for example, for broad-spectrum disease 
control or for resistance management to obtain the broadest 
benefits possible (Kjærstad et al. 2010a). Though current 
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risk assessment approaches are predominantly based on 
individual azole fungicides, human exposure is in general 
to complex mixtures of pesticides. It is therefore of interest 
to investigate the developmental potency of the mixture of 
antifungal compounds in the future research.
In conclusion, in the present study we provided further 
evidence that the ES-D3 cell differentiation assay, com-
bined with the in vitro BeWo transport model, is able to 
better predict the in vivo developmental toxicity ranking 
of the antifungal compounds, than as a stand-alone assay. 
At this stage, the applicability domain of this combined in 
vitro toxicodynamics and toxicokinetics approach is not 
known. Other series of compounds from different chemi-
cal classes should be tested to further evaluate the capac-
ity of this approach in predicting developmental toxicity. 
Since the method uses only in vitro assays to predict in 
vivo developmental toxicity ranking of chemicals, it can 
contribute to the 3Rs (replacement, reduction and refine-
ment) of animal testing. The predictive ability of the 
ES-D3 cell differentiation assay can most likely be fur-
ther enhanced if it is combined with more kinetic data and 
PBK modeling.
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